Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
In addition, there were no differences in daytime activity indices or in sleep parameters between the evening and morning initial treatment schedules
An initial analysis of the FDA adverse event reporting system (FAERS) data demonstrated no consistent trends in DKA with SGLT2i use over time [39], however an alternative cohort study of 50,220 individuals with type 2 diabetes showed the highest risk of DKA shortly after SGLT2i initiation, which subsequently reduced with time [40]
In: Program and abstracts of the American Diabetes Association (ADA) 68th Sessions, June 6-10, San Francisco, California
Clin Pharmacol Ther 1994;55(6):681-692
Research shows that patients who start GLP-1 therapy within 3 months of deciding to pursue it achieve 20% better outcomes than those who wait
